RNA Edge System by Asimov

RNA Edge System is a lab-in-the-loop platform developed by Asimov (Kernel) for AI-driven optimization of RNA therapy expression profiles. It is designed for biopharmaceutical organizations working on linear mRNA, circular RNA, and applications spanning cell therapy, genome editing, and vaccines. The platform takes programs from initial sequence design through wet lab validation, delivering high-confidence, data-backed candidates within weeks.

Most RNA sequences are still optimized using single-variable approaches, leaving performance potential unrealized. RNA Edge addresses this by simultaneously balancing multiple interdependent factors — translation dynamics, RNA secondary structure, and genetic element interactions — using a combination of proprietary computational models, high-performance genetic parts, and integrated experimental screening in application-relevant cell types.

Core Capabilities

• AI-driven sequence optimization targeting expression profile improvement across multiple variables simultaneously
• Development and use of novel genetic parts to enhance RNA performance
• Experimental validation conducted in cell types relevant to the intended therapeutic application
• Integrated screening combining computational and synthetic biology approaches
• Support for both linear mRNA and circular RNA formats

Therapeutic Applications

• Cell therapy programs, including CAR T-cell applications
• Genome editing, including Cas9-based programs
• Vaccine development
• Validated in large biopharma programs for CAR and Cas9 constructs

Workflow: Sequence to Validated Candidates

1. Input of target RNA sequence into the RNA Edge platform
2. Computational design and optimization using proprietary AI models and genetic parts
3. Wet lab screening and validation in application-relevant cell types
4. Delivery of top validated candidates with supporting data, typically within weeks

RNA Edge is offered by Asimov, headquartered in Boston, MA. The platform is positioned for use by biopharma organizations seeking to improve expression and durability of RNA therapeutics beyond what conventional single-variable optimization methods can achieve.